

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

FEB 04 2005

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of 1

Complete If Known

Application Number	10/696,464
Filing Date	October 29, 2003
First Named Inventor	Mammen et al.
Art Unit	1625
Examiner Name	Celia C. Chang

Attorney Docket Number

P-142-US1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
DP	A25	US 6,635,764 B2	10-21-2003	Mammen et al.	
	A26	US 6,693,202 B1	02-17-2004	Aggen et al.	
	A27	US 2004/0029919 A1	02-12-2004	Mammen et al.	
	A28	US 2004/0054187 A1	03-18-2004	Mammen et al.	
	A29	US 2004/0110229 A1	06-10-2004	Aggen et al.	
	A30	US 2004/0116706 A1	06-17-2004	Mammen et al.	
	A31	US 2005/0026954 A1	02-03-2005	Mammen et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
AK	B19	WO 99/64043 A1	12-16-1999	Advanced Medicine, Inc.		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature

Sarah Peeler

Date Considered

03/01/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete If Known

Application Number	10/696,464
Filing Date	October 29, 2003
First Named Inventor	Mathai MAMMEN
Art Unit	1614
Examiner Name	Not yet assigned

Attorney Docket Number

P-142-US1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
AP	A1	US-2002/0049195 A1	04-25-2002	Mammen et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature

Sarah Peilinger

Date Considered

03/01/106

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete If Known

Application Number	10/696,484
Filing Date	October 29, 2003
First Named Inventor	Mathai MAMMEN
Art Unit	1614
Examiner Name	Not yet assigned

Attorney Docket Number

P-142-US1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
DP	A1	US- 3,192,206	06-29-1965	Lunsford et al.	
	A2	US- 3,192,210	06-29-1965	Lunsford et al.	
	A3	US- 3,192,221	06-29-1965	Lunsford et al.	
	A4	US- 3,984,557	10-05-1976	Welstead, Jr.	
	A5	US- 4,002,768	01-11-1977	Welstead, Jr.	
	A6	US- 4,594,343	06-10-1988	Shanklin, Jr. et al.	
	A7	US- 4,810,713	03-07-1989	Yanni et al.	
	A8	US- 4,850,674	08-21-1990	Yanni et al.	
	A9	US- 5,028,858	08-25-1991	Vega-Noverola et al.	
	A10	US- 5,028,616	07-02-1991	Desai et al.	
	A11	US- 5,070,087	12-03-1991	Teng et al.	
	A12	US- 5,098,890	03-17-1992	Cross et al.	
	A13	US- 5,233,053	08-03-1993	Cross et al.	
	A14	US- 5,281,601	01-25-1994	Cross et al.	
	A15	US- 5,340,831	08-23-1994	Cross et al.	
	A16	US- 5,344,835	09-06-1994	Alker et al.	
	A17	US- 5,488,527	01-23-1996	Alker et al.	
	A18	US- 5,607,950	03-04-1997	Alker et al.	
	A19	US- 5,750,540	05-12-1998	Tsuchiya et al.	
	A20	US- 5,832,594	08-03-1999	Cross et al.	
	A21	US- 6,130,232	10-10-2000	Mase et al.	
	A22	US- 6,318,920 B1	11-20-2001	Caroon et al.	
	A23	US- 2003/0055080 A1	03-20-2003	Fomer et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
DP	B1	WO 91/09013 A1	06-27-1991	Pfizer Limited		
	B2	WO 99/43657 A1	09-02-1999	F. Hoffmann-La Roche AG		
	B3	WO 01/04118 A2	01-18-2001	Almirall Prodesfarma S. A.		
	B4	WO 02/051841 A1	07-04-2002	Almirall Prodesfarma, S. A.		
	B5	WO 02/053564 A2	07-11-2002	Almirall Prodesfarma AG		
	B6	WO 03/048124 A1	06-12-2003	F. Hoffmann-La Roche AG		
	B7	CH 628 885 A5 (in French language)	03-31-1982	Anphar S. A.		

Examiner Signature

Senah Peeling

Date Considered

03/01/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of 2

Attorney Docket Number

P-142-US1

Complete if Known

Application Number	10/696,464
Filing Date	October 29, 2003
First Named Inventor	Mathai MAMMEN
Art Unit	1614
Examiner Name	Not yet assigned

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
SP	B8	EP 0 178 946 A2	04-23-1986	A. H. Robins Company, Inc.		
	B9	EP 0 178 947 A2	04-23-1986	A. H. Robins Company, Inc.		
	B10	EP 0 235 463 A2	09-09-1987	A. H. Robins Company, Inc.		
	B11	EP 0 388 054 B1	09-19-1990	Pfizer Limited		
	B12	EP 0 863 141 A1	09-09-1998	Banyu Pharmaceutical Co., Ltd.		
	B13	EP 0 930 298 A1	07-21-1999	Banyu Pharmaceutical Co., Ltd.		
	B14	EP 0 999 205 A1	05-10-2000	Mitsubishi-Tokyo Pharmaceuticals, Inc.		
	B15	EP 1 020 449 A1	07-19-2000	Mitsubishi-Tokyo Pharmaceuticals, Inc.		
	B16	GB 1 507 462	04-12-1978	Antonio Gallardo, S. A.		
	B17	GB 1 575 310	09-17-1980	Anphan S. A.		
	B18	GB 1 593 851	07-22-1981	Antonio Gallardo S. A.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SP	C1	BROADLEY et al., "Muscarinic Receptor Agonists and Antagonists", Molecules 2001, 6, pp 142-193 (2001)	
	C2	EGLEN et al., "Muscarinic Receptor Subtypes: Pharmacology and Therapeutic Potential", DN&P, 10(8), pp 462-489 (1997)	
	C3	EGLEN et al., "Selective modulation of muscarinic receptor subtypes: therapeutic potential", Emerging Drugs: The Prospect for Improved Medicines/Annual Executive Briefing 1998; pp 67-79 (1998)	
	C4	GRAUL et al., "Darifenacin", Drugs of the Future 1996, 21 (11); pp 1105-1108 (1996)	
	C5	MORAGUES et al., "Dopaminergic Activity in a Series of N-Substituted 2-Aminopyrimidines", II Farmaco -Ed. Sc. -Vol. 35 - Fasc. 11; pp 951-964 (1980)	
	C6	SHUM et al., "The Design and Synthesis of Purine Inhibitors of CDK2.III", Nucleosides, Nucleotides & Nucleic Acids, 20(4-7), pp 1067-1078 (2001)	
	C7	ZLOTOS et al., "Muscarinic receptor agonists and antagonists", Exp. Opin. on Ther. Patents, 9(8), pp 1029-1053 (1999)	

Examiner Signature

Sarah Pelegar

Date Considered

03/01/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.